Hale G - Search Results

1

Moreau T, Coles A, Wing M, Thorpe J, Miller D, Moseley I, Issacs J, Hale G, Clayton D, Scolding N, Waldmann H, Compston A. Moreau T, et al. Among authors: hale g. Mult Scler. 1996 Jul;1(6):357-65. doi: 10.1177/135245859600100616. Mult Scler. 1996. PMID: 9345418

2

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis.

Moreau T, Thorpe J, Miller D, Moseley I, Hale G, Waldmann H, Clayton D, Wing M, Scolding N, Compston A. Moreau T, et al. Among authors: hale g. Lancet. 1994 Jul 30;344(8918):298-301. doi: 10.1016/s0140-6736(94)91339-0. Lancet. 1994. PMID: 7914262

3

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.

Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H, Compston A. Moreau T, et al. Among authors: hale g. Brain. 1996 Feb;119 ( Pt 1):225-37. doi: 10.1093/brain/119.1.225. Brain. 1996. PMID: 8624684

4

Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.

Wing MG, Moreau T, Greenwood J, Smith RM, Hale G, Isaacs J, Waldmann H, Lachmann PJ, Compston A. Wing MG, et al. Among authors: hale g. J Clin Invest. 1996 Dec 15;98(12):2819-26. doi: 10.1172/JCI119110. J Clin Invest. 1996. PMID: 8981930 Free PMC article.

5

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis.

Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G, Miller D, Waldmann H, Compston A. Coles AJ, et al. Among authors: hale g. Ann Neurol. 1999 Sep;46(3):296-304. doi: 10.1002/1531-8249(199909)46:3<296::aid-ana4>3.0.co;2-#. Ann Neurol. 1999. PMID: 10482259 Clinical Trial.

6

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis.

Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, Weetman A, Hale G, Chatterjee VK, Waldmann H, Compston A. Coles AJ, et al. Among authors: hale g. Lancet. 1999 Nov 13;354(9191):1691-5. doi: 10.1016/S0140-6736(99)02429-0. Lancet. 1999. PMID: 10568572 Clinical Trial.

7

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.

Hale G, Waldmann H. Hale G, et al. J Hematother. 1994 Spring;3(1):15-31. doi: 10.1089/scd.1.1994.3.15. J Hematother. 1994. PMID: 7922004 Clinical Trial.

8

Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.

Hale G, Waldmann H. Hale G, et al. Bone Marrow Transplant. 1994 May;13(5):597-611. Bone Marrow Transplant. 1994. PMID: 8054913

9

CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura.

Lim SH, Hale G, Marcus RE, Waldmann H, Baglin TP. Lim SH, et al. Among authors: hale g. Br J Haematol. 1993 Jul;84(3):542-4. doi: 10.1111/j.1365-2141.1993.tb03117.x. Br J Haematol. 1993. PMID: 8217808

10

CAMPATH-1H in inflammatory arthritis.

Watts RA, Isaacs JD, Hale G, Hazleman BL, Waldmann H. Watts RA, et al. Among authors: hale g. Clin Exp Rheumatol. 1993 Mar-Apr;11 Suppl 8:S165-7. Clin Exp Rheumatol. 1993. PMID: 8324942 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

743 results

Search Page